Skip to content
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
Contact
Subscribe
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Subscribe to our news
Contact
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
About us
Key figures
Our vision
Governance
Our CSR objectives
Membership
Platform
Microbiome Ecosystem Therapies
MET-N
MET-C
gutPrint®
cGMP manufacturing facility
Pipeline
Overview
Xervyteg®
MaaT033
MaaT034
MaaT03X
Scientific Publications
Patients & Healthcare Professionals
News
Corporate profile
Press Releases
Media Coverage
Posters
Videos
Investors
Stock information
Events & Presentations
Regulated information
Shareholders Meetings
CSR
Careers
Our values
Meet our people
Contact
Subscribe
Event
“Journée Microbiotes et Santé”
Date : January 24, 2025
Overview of the global microbiome landscape and highlight the role of patients in supporting innovation,
Sharing of the positive topline results from our Phase 3 study in acute GvHD
For more information, visit:
Journée Microbiotes et Santé 2025
Previous Post
17th « Journée GREFFE» of the IPC
Next Post
January 8, 2025: Drug From Bowel Bacteria Helps Blood Cancer Patients Facing Deadly Complication – Bloomberg
MaaT Pharma in the News